does cannabis help anxiety?

the randomised trials do not show it. a 2026 lancet psychiatry meta-analysis of 54 trials found no significant benefit of cannabinoids for anxiety, and a 2019 meta-analysis of 40 trials found only a very-low-certainty small improvement in anxiety in people whose main problem was another medical condition, with twice the odds of side effects. the cbd anxiety signal comes from single pharmaceutical doses in laboratory speech tests, where 300 mg worked and 150 mg and 600 mg did not. regular use is associated with more social anxiety disorder in the national academies’ 2017 review.

does cannabis help depression?

there is no randomised evidence that it does. the 2026 lancet psychiatry review found no randomised trial of cannabinoids for depression at all, and the national academies found limited evidence that cannabinoids are ineffective for depressive symptoms in people with chronic pain or multiple sclerosis. observationally, cannabis use is associated with a small increased risk of depressive disorders, and use before 18 with higher odds of depression and suicide attempts in young adulthood. those are associations, not proof of cause.

is any cannabis product fda approved for mental health?

no. the fda has approved dronabinol (marinol, syndros), synthetic thc, for aids-related weight loss and chemotherapy nausea; nabilone (cesamet), now listed as discontinued; and cannabidiol (epidiolex) for three rare seizure disorders. none has a psychiatric indication, and botanical cannabis has never been approved for any. the marinol label tells prescribers to avoid it in patients with a psychiatric history because dronabinol has been reported to exacerbate mania, depression and schizophrenia.

does cannabis cause psychosis or schizophrenia?

it is strongly associated with it, and the risk rises with use. the national academies rated the association substantial, with the highest risk among the most frequent users. heavy users have almost four times the odds of psychotic outcomes, and daily use of cannabis at 10% thc or more nearly five times. whether it causes psychosis is still argued: one genetic study found a small causal effect plus evidence that schizophrenia risk leads people to cannabis, another found a larger causal estimate. neither could measure dose or potency.

is cannabis legal federally now?

partly changed, mostly not. a final rule effective april 28, 2026 placed marijuana in schedule iii when it is in an fda-approved drug or covered by a state medical marijuana license. adult-use and all other cannabis remain in schedule i under 21 cfr 1308.11(d). a broader rescheduling proposal went to a dea hearing set for june 2026, and as of october 13, 2026 the federal register shows no final rule from it. state programmes regulate products under state standards.

Substance evidence

Cannabis and THC

What the controlled evidence shows, separated from the policy argument.

page first published 2026-09-08 · last updated 2026-10-13

Not an FDA-approved treatmentSold outside the supplement category5 studies on this page

What Its Legal Status Actually Means

Read this before anything below it. Legal to sell is not the same fact as reviewed, verified, or approved.

Botanical cannabis has never been FDA-approved for any psychiatric indication. Its federal scheduling changed partially in 2026 and is still unsettled: a DEA/DOJ final rule effective 28 April 2026 (Federal Register document 2026-08176) moved two narrow categories — marijuana contained in an FDA-approved drug product, and marijuana subject to a state medical marijuana license — from Schedule I to Schedule III, and 21 CFR 1308.13(g) now lists them there. Everything else, including adult-use and recreational cannabis, remains in Schedule I under 21 CFR 1308.11(d), alongside naturally occurring tetrahydrocannabinols. A separate proposal to reschedule marijuana broadly to Schedule III is still pending: DEA published a notice of hearing on 28 April 2026 setting proceedings to begin 29 June 2026, and as of 18 August 2026 no final rule broadly rescheduling marijuana had been published. Meanwhile most US states run medical and/or adult-use programmes whose products are regulated by state, not federal, standards. Some pharmaceutical cannabinoids (for example dronabinol) are separately FDA-approved for non-psychiatric uses such as chemotherapy-induced nausea and AIDS-related anorexia.

Quoted whole from the 2026-08-18 study harvest. Not summarized, not shortened.

does cannabis or thc help anxiety or depression? what the trials and the fda say

no cannabis product has an fda-approved psychiatric use. the label facts below are read from two fda labels on dailymed: marinol (dronabinol capsules, nda 018651), set id d0efeeec-640d-43c3-8f0a-d31324a11c68, version 5, effective february 14, 2023; and epidiolex (cannabidiol oral solution, nda 210365), set id 8bf27097-4870-43fb-94f0-f3d0871d1eec, version 35, effective may 29, 2026. approval dates are from drugs@fda. the scheduling facts are from the april 28, 2026 final rule in the federal register (document 2026-08176) and 21 cfr 1308.11(d) as published on ecfr for october 1, 2026. the evidence ratings are quoted from the national academies’ 2017 committee conclusions. every trial and cohort figure is from a study record on this page, each of which is a library row linked at the end. every source is linked at the end of this section. last checked 2026-10-13.

many people use cannabis to manage anxiety, sleep or low mood on their own. thc, delta-9-tetrahydrocannabinol, is the compound that produces the high; cbd, cannabidiol, is a different compound with its own page. the controlled evidence on thc for mental health is two lancet psychiatry meta-analyses of randomised trials, and both found no reliable benefit for anxiety, depression, ptsd or psychosis, with more side effects than placebo. the strongest evidence about cannabis and mental health is about harm, and that evidence is observational, so it carries its own limits. this section says what the law and the fda labels say, what the trials found in both directions, what the national academies concluded in 2017, and what the psychosis and depression cohorts can and cannot show. every number is from a study record on this page, an fda label, the federal register, or the national academies’ report, and each source is linked at the end.

this is information to take to a prescriber or pharmacist. nothing here tells anyone to use cannabis or to stop, nothing here is a reason to stop or change a prescribed medication, and nothing here is a reason to put off treatment that works.

what the law and the fda labels say

four cannabinoid medicines have been approved by the fda, and none has a psychiatric indication. dronabinol, synthetic thc, was approved as marinol capsules on may 31, 1985 and as syndros oral solution on july 1, 2016; both labels are for anorexia with weight loss in aids and for chemotherapy nausea and vomiting that has not responded to standard antiemetics [marinol-label 1; approvals]. nabilone, a synthetic cannabinoid, was approved as cesamet on december 26, 1985; drugs@fda now lists it as discontinued and dailymed carries no current nabilone label [approvals]. cannabidiol was approved as epidiolex on june 25, 2018 for seizures in lennox-gastaut syndrome, dravet syndrome and tuberous sclerosis complex, and its label says it "is not a controlled substance" [epidiolex-label 1, 9.1; approvals]. botanical cannabis has never been approved for any psychiatric use [status].

the marinol label is the closest thing to an fda statement on thc and mental illness, and it reads as a warning: "dronabinol has been reported to exacerbate mania, depression, or schizophrenia." it tells prescribers to screen for a history of these illnesses, to "avoid use in patients with a psychiatric history" or, if the drug cannot be avoided, to monitor for new or worsening psychiatric symptoms, and it notes that significant central nervous system symptoms followed oral doses of 0.4 mg per kilogram, 28 mg for a 70 kg patient, in antiemetic studies [marinol-label 5.1]. it adds cognitive impairment, impaired driving, low or high blood pressure, fainting and a fast heart rate, seizures, and a requirement to assess the risk of abuse in anyone with a history of substance use [marinol-label 5.1 to 5.4].

federal scheduling changed in part in 2026. a final rule effective april 28, 2026 placed marijuana in schedule iii when it is contained in an fda-approved drug product or is subject to a state medical marijuana license [fr-2026]. everything else stays in schedule i: 21 cfr 1308.11(d) still lists marihuana and naturally occurring tetrahydrocannabinols there [cfr]. a separate proposal to reschedule marijuana broadly was set for a dea hearing beginning june 29, 2026 [status]; as of october 13, 2026 the federal register shows no final rule from it. most states run medical or adult-use programmes whose products meet state standards, not federal drug standards [status].

what the trials measured

two meta-analyses in lancet psychiatry carry the randomised evidence. the 2019 review pooled 40 randomised trials in 3,067 people across depression, anxiety, adhd, tourette syndrome, ptsd and psychosis [black-2019]. the 2026 review pooled 54 randomised trials in 2,477 people across mental disorders and substance use disorders, and found no randomised trial at all of cannabinoids for depression [wilson-2026]. the cbd trials for anxiety are single-dose laboratory challenges: 24 people with untreated social anxiety disorder took 600 mg of cbd or placebo before a simulated public speech [bergamaschi-2011], and 57 healthy men took 150, 300 or 600 mg or placebo before the same test [linares-2019].

what the research says, in both directions

in favour. in the 2019 review, pharmaceutical thc produced a small improvement in anxiety in people whose main problem was another medical condition (standardised mean difference -0.25), at very low certainty [black-2019]. the 2026 review found small effects, all at low certainty, for cannabis withdrawal (-0.29), tic severity in tourette syndrome (-0.68), sleep time in insomnia, and autistic traits [wilson-2026]. the national academies rated the evidence "conclusive or substantial" that cannabis is effective for chronic pain in adults and that oral cannabinoids treat chemotherapy nausea, "moderate" that cannabinoids, mainly nabiximols, improve short-term sleep in people whose sleep is disturbed by sleep apnea, fibromyalgia, chronic pain or multiple sclerosis, and "limited" that cbd improves anxiety on a public speaking test in social anxiety disorder and that nabilone improves ptsd symptoms, the last from "one single, small fair-quality trial" [nasem-2017]. in the laboratory, a single 600 mg dose of cbd reduced anxiety, cognitive impairment and discomfort during a simulated speech in people with social anxiety disorder [bergamaschi-2011].

against, or smaller than it sounds. the 2019 review found thc did not significantly improve any other primary outcome, worsened negative symptoms of psychosis in the one trial that measured them (0.36), roughly doubled the odds of adverse events (odds ratio 1.99), and nearly tripled the odds of dropping out because of them (2.78) [black-2019]. the 2026 review found no significant benefit for anxiety, ptsd, psychotic disorders, anorexia nervosa or opioid use disorder, more adverse events on cannabinoids (odds ratio 1.75), and one extra person harmed for every seven treated [wilson-2026]. the national academies found "limited evidence" that cannabinoids are ineffective for depressive symptoms in chronic pain or multiple sclerosis, and no or insufficient evidence for mental health outcomes in schizophrenia with cbd [nasem-2017]. the cbd anxiety signal shrinks on inspection: it comes from one-off pharmaceutical doses in laboratory tests, not weeks of use, and in the dose-ranging trial only 300 mg worked while 150 mg and 600 mg did no better than placebo [linares-2019; cbd-page]. none of the trials tested the products people buy at a dispensary, at the thc potencies sold now.

psychosis, depression and suicide: what the cohorts show and cannot show

psychosis. the national academies rated the association between cannabis use and "the development of schizophrenia or other psychoses, with the highest risk among the most frequent users" as substantial, their second-highest grade [nasem-2017]. across 10 studies and 66,816 people, the heaviest users had almost four times the odds of schizophrenia and related outcomes compared with non-users (odds ratio 3.90, 95% ci 2.84 to 5.34), and every included study showed higher risk at higher use [marconi-2016]. comparing 901 people with first-episode psychosis with 1,237 controls across 11 sites, daily use was associated with about three times the odds (adjusted odds ratio 3.2) and daily use of high-potency cannabis, 10% thc or more, with nearly five times the odds (4.8); assuming causality, the authors estimated that removing high-potency cannabis would prevent 12.2% of first-episode psychosis across the sites, 30.3% in london and 50.3% in amsterdam [diforti-2019]. after a first episode, among 256 patients followed for two years, former regular users who stopped had the most favourable course in simple analyses, and continued daily use of high-potency cannabis carried about three times the odds of relapse (odds ratio 3.28) [schoeler-2016].

the other direction on psychosis. association is not causation, and the genetic studies disagree on size. a 2017 mendelian randomisation study found "some evidence consistent with a causal effect" of cannabis on schizophrenia but a small one (odds ratio 1.04), and stronger evidence that genetic risk for schizophrenia raises the chance of starting cannabis (1.10), which means part of the link may run the other way [gage-2017]. a 2018 study using different genetic data estimated an odds ratio of 1.37 for users against non-users and concluded the relationship is causal [vaucher-2018]. neither genetic study could measure dose, potency or age at first use, the factors the cohorts point to [gage-2017; vaucher-2018].

depression, suicide and mania. pooling 11 longitudinal studies of 23,317 people, cannabis use before 18 was associated with higher odds of major depression in young adulthood (odds ratio 1.37), suicidal ideation (1.50) and suicide attempt (3.46), while the link with anxiety was not statistically significant (1.18, 95% ci 0.84 to 1.67) [gobbi-2019]. the authors call the individual risk moderate to low and the population effect large [gobbi-2019]. the national academies rated the evidence moderate for a small increased risk of depressive disorders, for more suicidal ideation and attempts with higher incidence among heavier users, for more mania and hypomania in people with bipolar disorder who use regularly, and for more social anxiety disorder with regular use; it found no evidence to support or refute an effect on the course of depressive disorders [nasem-2017]. it also rated as substantial the association between more frequent use and progression to problem cannabis use, and named earlier age at first use as a risk factor [nasem-2017].

questions for a prescriber or pharmacist about cannabis

each one comes from a warning or a study above. they are questions, not instructions; the answers depend on a history nobody here has.

i use cannabis for anxiety, sleep or mood. two meta-analyses of randomised trials found no reliable benefit for anxiety, ptsd or psychosis and no trials at all for depression. what would you suggest we look at instead, or alongside?
is there psychosis, schizophrenia or bipolar disorder in my family? the risk in the cohorts rose with frequency and potency, and the marinol label says thc has been reported to exacerbate mania, depression and schizophrenia.
i take an antidepressant, a benzodiazepine, an opioid, lithium or a sleep medicine. the marinol label lists those among drugs that add to thc’s sedation and impairment. does anything i take matter here?
how would we tell whether cannabis is helping my anxiety or whether withdrawal between uses is part of the anxiety?
if i am a teenager or the parent of one: the cohort evidence on depression and suicide attempts concerns use before 18. what should we watch for?
if i have had a psychotic episode: the people who stopped regular use had the fewest relapses, and daily high-potency use the most. what does my pattern mean for my treatment plan?

questions people ask

does cannabis help anxiety?: the randomised trials do not show it. a 2026 lancet psychiatry meta-analysis of 54 trials found no significant benefit of cannabinoids for anxiety, and a 2019 meta-analysis of 40 trials found only a very-low-certainty small improvement in anxiety in people whose main problem was another medical condition, with twice the odds of side effects. the cbd anxiety signal comes from single pharmaceutical doses in laboratory speech tests, where 300 mg worked and 150 mg and 600 mg did not. regular use is associated with more social anxiety disorder in the national academies’ 2017 review.
does cannabis help depression?: there is no randomised evidence that it does. the 2026 lancet psychiatry review found no randomised trial of cannabinoids for depression at all, and the national academies found limited evidence that cannabinoids are ineffective for depressive symptoms in people with chronic pain or multiple sclerosis. observationally, cannabis use is associated with a small increased risk of depressive disorders, and use before 18 with higher odds of depression and suicide attempts in young adulthood. those are associations, not proof of cause.
is any cannabis product fda approved for mental health?: no. the fda has approved dronabinol (marinol, syndros), synthetic thc, for aids-related weight loss and chemotherapy nausea; nabilone (cesamet), now listed as discontinued; and cannabidiol (epidiolex) for three rare seizure disorders. none has a psychiatric indication, and botanical cannabis has never been approved for any. the marinol label tells prescribers to avoid it in patients with a psychiatric history because dronabinol has been reported to exacerbate mania, depression and schizophrenia.
does cannabis cause psychosis or schizophrenia?: it is strongly associated with it, and the risk rises with use. the national academies rated the association substantial, with the highest risk among the most frequent users. heavy users have almost four times the odds of psychotic outcomes, and daily use of cannabis at 10% thc or more nearly five times. whether it causes psychosis is still argued: one genetic study found a small causal effect plus evidence that schizophrenia risk leads people to cannabis, another found a larger causal estimate. neither could measure dose or potency.
is cannabis legal federally now?: partly changed, mostly not. a final rule effective april 28, 2026 placed marijuana in schedule iii when it is in an fda-approved drug or covered by a state medical marijuana license. adult-use and all other cannabis remain in schedule i under 21 cfr 1308.11(d). a broader rescheduling proposal went to a dea hearing set for june 2026, and as of october 13, 2026 the federal register shows no final rule from it. state programmes regulate products under state standards.

sources for this section

the library rows link to our one-page summary of each study, with the original paper, its funding and our evidence grade on that page.

What the Research Shows

5 records from the 2026-08-18 harvest, each checked against PubMed and Europe PMC on that date. How a study was designed, how many people were in it, and who paid for it are printed above what it found, because those three facts decide how much the finding is worth.

Study 1 · 2026
- Meta-analysis of randomized trials
- 2,477 participants
- Top-tier journal
- Independently funded
- Preregistered
- Declared conflicts of interest
gold standard98/100
Top of the evidence hierarchy, independently funded.
Across 54 randomised trials and 2,477 participants, cannabinoids showed no significant benefit for anxiety, PTSD, psychotic disorders, anorexia nervosa, or opioid use disorder, and there were no randomised trials at all of cannabinoids for depression. Small effects were seen for cannabis withdrawal (SMD -0.29), tic severity in Tourette syndrome (SMD -0.68), sleep time in insomnia, and autistic traits, all at low certainty; adverse events were more frequent with cannabinoids (OR 1.75, number needed to harm 7).
Wilson J, Dobson O, Langcake A, et al. (2026). The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. Lancet Psychiatry. PMID 41856154.
How this record was checked
PubMed record 41856154 fetched via NCBI efetch 2026-08-18; title, authors, journal, year, DOI, 54 trials, n=2477, and the specific effect estimates confirmed from the abstract. Funding read directly off the record's FUNDING field ("The National Health and Medical Research Council"), hence INDEPENDENT; PROSPERO registration CRD42023392718 and the declaration-of-interests statement also read off the record. Record carries an "Erratum in" notice (Lancet Psychiatry 2026;13(8):e11), not a retraction.
Study 2 · 2019
- Meta-analysis of randomized trials
- 3,067 participants
- Top-tier journal
- Independently funded
- Preregistered
- Declared conflicts of interest
gold standard98/100
Top of the evidence hierarchy, independently funded.
Pooling 40 randomised trials (n=3,067) across depression, anxiety, ADHD, Tourette syndrome, PTSD, and psychosis, pharmaceutical THC produced only a very-low-certainty small improvement in anxiety among people whose primary problem was another medical condition (SMD -0.25), worsened negative symptoms of psychosis in the single trial that measured it (SMD 0.36), and did not significantly affect any other primary outcome. It roughly doubled the odds of adverse events (OR 1.99) and nearly tripled withdrawals due to adverse events (OR 2.78).
Black N, Stockings E, Campbell G, et al. (2019). Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. PMID 31672337.
How this record was checked
PubMed record 31672337 fetched via NCBI efetch 2026-08-18; title, authors, journal, year, DOI, 83 studies / 40 RCTs / n=3067, and the effect estimates confirmed from the abstract. Funding read off the record's FUNDING field (Therapeutic Goods Administration Australia; Commonwealth Department of Health; NHMRC; US NIH), hence INDEPENDENT; five PROSPERO registrations and the conflicts statement also read off the record. Record carries "Erratum in" and "Comment in" notices, no retraction.
Study 3 · 2019
- Case-control study
- 2,138 participants
- Top-tier journal
- Independently funded
moderate68/100
Reasonable evidence with real limitations.
Read this first: This is a case-control design, so it establishes association and a dose-response pattern rather than proving causation; reverse causation (early psychotic symptoms driving heavier use) and residual confounding cannot be fully excluded, which is why the authors flag the population-attributable fractions as conditional on causality.
Comparing 901 people presenting with first-episode psychosis against 1,237 population controls across 11 European and Brazilian sites, daily cannabis use was associated with about three times the odds of psychotic disorder (adjusted OR 3.2, 95% CI 2.2-4.1) and daily use of high-potency cannabis (THC 10% or more) with nearly five times the odds (OR 4.8, 2.5-6.3). Assuming causality, removing high-potency cannabis would prevent an estimated 12.2% of first-episode psychosis across all sites, 30.3% in London, and 50.3% in Amsterdam.
Di Forti M, Quattrone D, Freeman TP, et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. PMID 30902669.
How this record was checked
PubMed record 30902669 fetched via NCBI efetch 2026-08-18; title, authors, journal, year, DOI, 901 cases and 1,237 controls (n=2,138 total), and all odds ratios and population-attributable fractions confirmed from the abstract. Funding read off the record's FUNDING SOURCE field (Medical Research Council, EU FP7, São Paulo Research Foundation, NIHR Biomedical Research Centres, Wellcome Trust), hence INDEPENDENT. No conflict-of-interest statement present in the record, so conflicts recorded false.
Study 4 · 2019
- Systematic review of observational studies
- 23,317 participants
- Top-tier journal
- Independently funded
- Declared conflicts of interest
strong83/100
Well-supported by good-quality research.
Read this first: One co-author (Ware) became an employee of Canopy Growth Corporation, a licensed cannabis producer, after the work was completed, and the senior author discloses an unrelated cannabidiol grant involving Aurora Cannabis; both were disclosed. The pooled estimates come from observational studies, so residual confounding by shared risk factors for cannabis use and depression cannot be excluded.
Pooling 11 longitudinal studies covering 23,317 people, cannabis use before age 18 was associated with modestly higher odds of major depression in young adulthood (OR 1.37, 95% CI 1.16-1.62) and of suicidal ideation (OR 1.50, 1.11-2.03) and suicide attempt (OR 3.46, 1.53-7.84); the association with anxiety was not statistically significant (OR 1.18, 0.84-1.67). Individual-level risk is moderate to low, but the authors note that at population scale this translates into a large number of affected young people.
Gobbi G, Atkin T, Zytynski T, et al. (2019). Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry. PMID 30758486.
How this record was checked
PubMed record 30758486 fetched via NCBI efetch 2026-08-18; title, authors, journal, year, DOI, 11 studies, n=23,317, and all four odds ratios confirmed from the abstract. PMC record 6450286 fetched the same day carries the Funding/Support statement (Canadian Institutes of Health Research knowledge synthesis grant 147991 and the Quebec Network on Suicide, Mood Disorders and Related Disorders; funders had no role), hence INDEPENDENT, plus the conflict disclosures quoted above. Record carries an "Erratum in" notice, no retraction.
Study 5 · 2016
- Systematic review of observational studies
- 66,816 participants
- Reputable journal
- Funding not established
moderate59/100
Reasonable evidence with real limitations.
Read this first: Built entirely from observational studies with heterogeneous definitions of "heavy" use; the pooled odds ratio was generated by simulating individual data points from summary statistics, a method that depends on assumptions about the underlying distributions.
Across 10 studies and 66,816 people, the heaviest cannabis users had almost four times the odds of schizophrenia and related psychotic outcomes compared with non-users (OR 3.90, 95% CI 2.84-5.34), and every included study showed higher risk at higher levels of use. The consistent dose-response gradient is what makes this association hard to dismiss as confounding alone, though the authors stop short of claiming proof of causation.
Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. (2016). Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophrenia Bulletin. PMID 26884547.
How this record was checked
PubMed record 26884547 fetched via NCBI efetch 2026-08-18; title, authors, journal, year, DOI, 18 studies reviewed / 10 meta-analysed, n=66,816, and OR 3.90 (2.84-5.34) confirmed from the abstract. PMC record 4988731 fetched the same day returns front matter and abstract only with no readable funding statement, so funding is recorded UNKNOWN despite Europe PMC listing MRC and NIHR grant tags against the record, and independence is left unchecked.

The Risks

Nobody checks this purchase the way a prescription is checked. No prescriber reviews it against the rest of what you take, no pharmacist screens the interaction, and no regulator confirms the dose in the capsule before it is sold. That is why this section sits here at full length rather than as a footnote.

What the paragraph below covers:

Suicidal thoughts or behavior
Heart and blood pressure
Psychosis and mania
Dependence and withdrawal
Drug interactions
Sleep disruption
Stomach and gut

The dose-response relationship between cannabis and psychosis is one of the better replicated findings in psychiatric epidemiology: heavier use carries roughly a three-to-four-fold increase in psychosis risk, and daily use of high-potency (THC 10% or more) product carries close to a five-fold increase. Cannabis use disorder is common — dependence, tolerance, and a withdrawal syndrome of irritability, insomnia, appetite loss, and craving. Adolescent use is prospectively associated with depression and suicidality in young adulthood. In randomised trials, THC-containing cannabinoids worsened negative symptoms of psychosis and roughly doubled the odds of adverse events and of dropping out because of them. Acute effects include anxiety and panic (a common reason people stop), impaired driving, and cannabinoid hyperemesis syndrome with chronic heavy use. THC interacts with alcohol and other CNS depressants, and daily inhaled use has been linked to cardiovascular events. Using cannabis to self-treat anxiety or depression risks worsening the condition it is meant to help.

What Is Not Known

The boundaries of the section above, in the harvest’s own words. What it excluded, why, and where it looked and found nothing. An absence of evidence is not evidence of absence, and it is not evidence of benefit either.

What Was Left Out, and Why

Quoted from the harvest, where these notes sat above the study list rather than after it. Where a note says “below” it means the studies in the section above.

Cannabidiol-only evidence lives in cannabidiol.yaml; this file covers THC-containing cannabis and pharmaceutical cannabinoids.
Individual state-registry and dispensary self-report surveys of "medical cannabis for anxiety/PTSD" excluded: they are uncontrolled, self-selected, and subsumed by the two Lancet Psychiatry meta-analyses below.
Hsu 2026 JAMA clinical review (PMID 41296368) was verified but excluded as a narrative review that would add nothing the meta-analyses do not already carry.
The honest summary: the strongest evidence about cannabis and mental health is about harm, not benefit. That asymmetry is deliberate and is what the record shows.

The Retraction Check

PubMed efetch records for all five PMIDs (41856154, 31672337, 30902669, 30758486, 26884547) inspected 2026-08-18 for "Retraction in" flags; none present. Black 2019 and Gobbi 2019 carry "Erratum in" notices and Wilson 2026 carries one; these are corrections, not retractions, and are noted in the records below.

Questions for a Prescriber or Pharmacist

This page does not tell anyone to take Cannabis and THC or to avoid it. It is not able to: it does not know what else you take, what you have tried, or what you are treating. These are the questions each study above raises, written to be asked out loud.

Given that the 2026 trial review found no benefit for anxiety, PTSD, or psychosis and no depression trials at all, what evidence-based option should I be on instead of self-medicating with cannabis?
This review found THC did not help any mental-health outcome but doubled the odds of side effects — if I am using cannabis for my mood, what are we actually trading away?
Given my family history and the potency of what is sold now, what is my personal risk of a psychotic episode if I keep using cannabis daily?
My teenager is using cannabis — what does the depression and suicide-risk evidence mean for them specifically, and what should we do about it now?
If risk rises with how much I use, is cutting down meaningfully protective, or does the evidence only support stopping?

And the one to ask at the counter, whatever the answers above turn out to be: given everything I am already taking, what would you want to know about Cannabis and THC before I put it in the same body?

Open Cannabis and THC in veisund

The app has the resources behind this page and people working through the same questions.What you post there goes to people, not to a model. If someone answers, it is a person who has been there. The one automated message is a crisis-resource reply.

Where This Page Comes From

Transcribed from the study-harvest-2026-08-18 record for cannabis-thc, built into this page by scripts/supplement-ingest.mjs on 2026-09-07. Nothing here is fetched at page load, and nothing here was written by a model without a citation behind it.

Source file	study-harvest/2026-08-18/cannabis-thc.yaml
Source repo	REPTechnologies/avalo-backend
SHA-256	9d7372ad250da7d426199feafe6e3021eb6faf267b2a1743bcb585d5886bd6db
Also searched as	marijuana, weed, THC, delta-9-tetrahydrocannabinol, medical cannabis, dronabinol, nabiximols

The Other Substances

Do any supplements actually work? asks the question across all of them. The full library has the medication records, the funding investigations, and the glossary.